BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

...the team’s ongoing studies to yield additional deaminases to feed their pipeline. Targets ND4 - NADH dehydrogenase...
...subunit 4 Danielle Kopke, Staff Writer Broad Institute of MIT and Harvard University of Washington Editas Medicine Inc. Beam Therapeutics Inc. NADH dehydrogenase...
BioCentury | Apr 9, 2020
Finance

Wuhan gene therapy play Neurophth raises $18M series A

...virus infection and amplification in host cells. Targets ND4 - NADH dehydrogenase subunit 4 Hongjiang Li, Staff Writer NADH dehydrogenase...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...“I hope our success will spur others to try to develop neuroprotectants.” Targets ND2 - NADH dehydrogenase...
BioCentury | Feb 15, 2019
Clinical News

GenSight's GS010 misses in second Phase III for Leber hereditary optic neuropathy

...for six months or less that was due to the G11778A mutation in the mitochondrial NADH dehydrogenase...
...JAMA Ophthalmology. GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Product: GS010 (rAAV2/2-ND4) Business: Ophthalmic Molecular target: NADH dehydrogenase...
...data; Phase I/II data Milestone: Additional Phase III data (April 2019; 3Q19) Chris Lieu GS010 (RAAV2/2_ND4) GenSight Biologics S.A. NADH dehydrogenase...
BioCentury | Apr 6, 2018
Clinical News

GenSight's GS010 misses in Phase III for neuropathy

...vision loss of 6-12 months that was due to the G11778A mutation in the mitochondrial NADH dehydrogenase...
...one year. GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Product: GS010 (rAAV2/2-ND4) Business: Ophthalmic Molecular target: NADH dehydrogenase...
...fiber layer thickness Status: Phase III data Milestone: Phase III data (3Q18) Jennie Walters RAAV2/2_ND4 (GS010) GenSight Biologics S.A. NADH dehydrogenase...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

...Archives Indication Target Description Company or Institution Notes Therapeutic targets Autoimmune disease Osteoarthritis Mitochondrially encoded NADH dehydrogenase...
BioCentury | Apr 4, 2018
Clinical News

GenSight falls after Phase III neuropathy miss

...vision loss of 6-12 months that was due to the G11778A mutation in the mitochondrial NADH dehydrogenase...
...treat LHON with an onset of vision loss of less one year. Jennie Walters RAAV2/2_ND4 (GS010) GenSight Biologics S.A. NADH dehydrogenase...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Autoimmune disease

...testing MT-ND1 inhibitors or hydrogel-based antioxidants in patients with closed pilon fractures. TARGET/MARKER/PATHWAY: Mitochondrially encoded NADH dehydrogenase...
...Mitchell C. Coleman, University of Iowa, Iowa City, Iowa email: mitchell-coleman@uiowa.edu Winnie Pong AutoImmune University of Iowa Mitochondrially encoded NADH dehydrogenase...
BioCentury | Feb 22, 2017
Clinical News

GS010: Completed Ph III REVERSE enrollment

...GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Product: rAAV2/2-ND4 ( GS010 ) Business: Ophthalmic Molecular target: NADH dehydrogenase...
...Phase III enrollment Milestone: Complete Phase III enrollment (1H17); Phase III data (1Q18) Julian Zhu GS010 rAAV2/2_ND4 GenSight Biologics S.A. NADH dehydrogenase...
BioCentury | Nov 30, 2016
Distillery Techniques

Biomarkers

...responses in Huntington’s disease (HD). In a mouse model of HD, low plasma levels of NADH dehydrogenase...
...Mochly-Rosen, Stanford University School of Medicine, Stanford, Calif. email: mochly@stanford.edu Esme Gaisford Mitoconix Bio Ltd. Stanford University 8-oxo-2'-deoxyguanosine (8-oxo-2dG) Interleukin-6 (IL-6) NADH dehydrogenase...
Items per page:
1 - 10 of 21